Patents Assigned to The University of Montana
-
Publication number: 20140197098Abstract: A process of growing a culture of cyanobacteria or algae using chitin or chitosan as a source of nitrogen for photosynthetic growth is described. This process can be used to remove pollutants from nitrogen-deficient natural waters or wastewaters. Biomass that results from photosynthetic growth on chitin can be used, either as whole cells or the isolated components of the cells, for a large variety of commercial purposes.Type: ApplicationFiled: February 14, 2014Publication date: July 17, 2014Applicant: The University of MontanaInventors: Carrine Blank, Nancy W. Hinman
-
Patent number: 8673619Abstract: A process of growing a culture of cyanobacteria or algae using chitin or chitosan as a source of nitrogen for photosynthetic growth is described. This process can be used to remove pollutants from nitrogen-deficient natural waters or wastewaters. Biomass that results from photosynthetic growth on chitin can be used, either as whole cells or the isolated components of the cells, for a large variety of commercial purposes.Type: GrantFiled: March 26, 2012Date of Patent: March 18, 2014Assignee: The University of MontanaInventors: Carrine E. Blank, Nancy W. Hinman
-
Publication number: 20140066529Abstract: Silica polyamine composites (SPC) made from silanized amorphous nano-porous silica gel and poly(allylamine) (BP-1) were functionalized with phosphorus acid using the Mannich reaction, resulting in a phosphonic acid modified composite (BPAP). Zirconium (IV) was immobilized on BPAP. Arsenate anions strongly adsorbed on the ZrBPAP composite in the pH range 2 to 8, while arsenite only adsorbed well at pH 10. Regeneration of the resin was carried out successfully for As(V) and As(III) using 2M-H2SO4. Four adsorption/desorption cycles were performed for As(V) at pH 4 without significant decrease in the uptake performance. ZrBPAP capture capacity and kinetics for arsenate were tested for longevity over 1000 cycles with only a marginal loss of performance.Type: ApplicationFiled: November 6, 2013Publication date: March 6, 2014Applicant: The University of MontanaInventors: Edward Rosenberg, Varadharajan Kailasam, Daniel Nielsen
-
Patent number: 8623943Abstract: Hydroxypolyamides, hydroxypolyamide products, and post-hydroxypolyamides are disclosed as gel forming agents. Hydroxypolyamides and post-hydroxypolyamides are prepared from known methods. Hydroxypolyamide products are produced from a modified polymerization procedure which utilizes strong base for deprotonation of ammonium salts from the esterification of stoichiometrically equivalent polyacid:polyamine salts. The hydroxypolyamide products are capable of gel formation at lower concentrations than hydroxypolyamides and post-hydroxypolyamides from the known methods of preparation, and are therefore superior gel forming agents.Type: GrantFiled: November 17, 2008Date of Patent: January 7, 2014Assignee: The University of MontanaInventors: Donald E. Kiely, Tyler N. Smith
-
Publication number: 20130343994Abstract: The invention provides compounds that inhibit cholinesterases, such as acetylcholinesterase and butyrylcholinesterase. Such compounds are useful to prevent or treat exposure of a patient (e.g., a human) to an organophosphoric nerve agent (e.g., sarin and VX) or to treat a patient suffering from a neurodegenerative disorder such as Alzheimer's Disease or Lewy Body Dementia. The compounds are further useful as diagnostic tools for use in medical or research radiography (e.g., positron emission tomography) when synthesized with a radionuclide (e.g., [18F]. Synthetic schemes to produce such compounds are also provided.Type: ApplicationFiled: June 25, 2013Publication date: December 26, 2013Applicant: THE UNIVERSITY OF MONTANAInventors: Charles M. Thompson, John M. Gerdes, Syed K. Ahmed, Yamina Belabassi
-
Publication number: 20130261133Abstract: The compounds of the invention exhibit antiprotozoal, antimicrobial, and anticancer properties that are useful for the treatment or prevention of infections or cancer in a patient (e.g., a human). For example, the compounds and methods described herein can be used for the treatment or prevention of protozoal infections such as leishmaniasis, malaria, and trypanosoma infections, bacterial infections such as S. aureus and C. albicans, and cancers such as breast, colon, lung, or prostate cancer. The invention further provides methods of synthesizing such compounds as well as kits useful for administering the compounds.Type: ApplicationFiled: March 14, 2013Publication date: October 3, 2013Applicant: The University of MontanaInventors: John Howard Hoody, David Brian Bolstad
-
Patent number: 8535528Abstract: Oxine ligands placed on styrene base ion exchange resins selectively remove iron and gallium from acidic solutions. After loading, the oxine resin is stripped of the loaded metals and used again for further metal removal. The resins can be used for process streams, acid rock drainages, or any other iron or gallium containing solution.Type: GrantFiled: January 25, 2010Date of Patent: September 17, 2013Assignee: Montana Tech of The University Of MontanaInventors: Paul J. Miranda, Corby G. Anderson, Edward Rosenberg
-
Patent number: 8343446Abstract: The oxine ligands 5-chloro-8-hydroxyquiniline and 5-sulfoxyl-8-hydroxyquinoline are covalently bound, using, for example, the Mannich reaction, to a silica gel polyamine composite made from a silanized amorphous silica xerogel and polyallylamine. The resulting modified composites, termed CB-1 (X?Cl) and SB-1 (X?SO3H), respectively, show a clear selectivity for trivalent over divalent ions and selectivity for gallium over aluminum. The compounds of the invention can be applied for the sequestration of metals, such as heavy metals, from contaminated mine tailing leachates.Type: GrantFiled: October 13, 2011Date of Patent: January 1, 2013Assignee: The University of MontanaInventors: Edward Rosenberg, Paul Miranda, Yuen Onn Wong
-
Patent number: 8150643Abstract: Real-time battery impedance spectrum is acquired using a one-time record. Fast Summation Transformation (FST) is a parallel method of acquiring a real-time battery impedance spectrum using a one-time record that enables battery diagnostics. An excitation current to a battery is a sum of equal amplitude sine waves of frequencies that are octave harmonics spread over a range of interest. A sample frequency is also octave and harmonically related to all frequencies in the sum. The time profile of this signal has a duration that is a few periods of the lowest frequency. The voltage response of the battery, average deleted, is the impedance of the battery in the time domain. Since the excitation frequencies are known and octave and harmonically related, a simple algorithm, FST, processes the time record by rectifying relative to the sine and cosine of each frequency. Another algorithm yields real and imaginary components for each frequency.Type: GrantFiled: June 30, 2008Date of Patent: April 3, 2012Assignees: Battelle Energy Alliance, LLC, Montana Tech of the University of Montana, Qualtech Systems, Inc.Inventors: John L. Morrison, William H. Morrison, Jon P. Christophersen
-
Patent number: 7998962Abstract: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radiolabelled 2?-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2?-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain.Type: GrantFiled: September 22, 2010Date of Patent: August 16, 2011Assignee: The University of MontanaInventors: John M. Gerdes, David B. Bolstad, Brian R. Kusche
-
Publication number: 20110105621Abstract: A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, the dose is increased in response to a delay in administration. The invention also relates to a method for modulating cytokine expression within the brain to treat such conditions.Type: ApplicationFiled: November 24, 2010Publication date: May 5, 2011Applicant: THE UNIVERSITY OF MONTANAInventors: David J. Poulsen, Thomas Frederick Rau
-
Patent number: 7887784Abstract: Racemic mixtures and enantiomerically pure forms of novel 1-[(2?-substituted)-piperazin-1?-yl]-isoquinolines are norepinephrine (NE) transporter (NET) inhibitor compounds. Compounds of the invention are considered therapeutic agents for central nervous system (CNS) diseases and disorders, without limitation, including neurodegeneration, anxiety, depression, attention deficit disorders, drug dependency, and post traumatic stress disorder. Examples of the chemical syntheses of the compounds of the invention are provided. The isoquinoline compounds of the invention competitively bind at NET at nanomolar concentrations. The isoquinoline agents of the invention bind selectively to NET over other competitive transporter targets and receptor binding sites, including those of serotonin and dopamine, amongst others. The chemical syntheses of the invention are suitable for labeling with radionuclide atoms.Type: GrantFiled: March 21, 2008Date of Patent: February 15, 2011Assignee: University of MontanaInventors: John M. Gerdes, David B. Bolstad, Michael R. Braden, August W. Barany
-
Publication number: 20100272744Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.Type: ApplicationFiled: April 9, 2010Publication date: October 28, 2010Applicant: THE UNIVERSITY OF MONTANAInventors: RALPH C. JUDD, D. SCOTT MANNING
-
Patent number: 7812162Abstract: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radio-labelled 2?-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2?-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain.Type: GrantFiled: April 26, 2007Date of Patent: October 12, 2010Assignee: The University of MontanaInventors: John M. Gerdes, David B. Bolstad, Brian R. Kusche
-
Patent number: 7794733Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.Type: GrantFiled: June 26, 2003Date of Patent: September 14, 2010Assignee: The University of MontanaInventors: Ralph C. Judd, D. Scott Manning
-
Patent number: 7692041Abstract: A controlled nitric acid process employing oxygen and nitric acid as co-oxidants is used to oxidize organic compounds subject to nitric acid oxidation, to their corresponding carboxylic acids. Oxidation of some carbohydrates by this process can produce one or more of their corresponding acid forms. The process is carried out at moderate temperatures, typically in the range of 20° C. to 45° C. in a closed reactor, with oxygen gas being introduced into the reaction chamber as needed in order to sustain the reaction. Computer controlled reactors allow for careful and reproducible control of reaction parameters. Nitric acid can be recovered by a distillation/evaporation process, or by diffusion dialysis, the aqueous solution made basic with inorganic hydroxide, and the residual inorganic nitrate removed using a filtration (nanofiltration) device.Type: GrantFiled: August 6, 2007Date of Patent: April 6, 2010Assignee: The University of MontanaInventors: Donald E. Kiely, Kirk R. Hash, Sr.
-
Patent number: 7662588Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.Type: GrantFiled: November 29, 2006Date of Patent: February 16, 2010Assignee: The University of MontanaInventors: Ralph C. Judd, D. Scott Manning
-
Patent number: 7395163Abstract: Real time battery impedance spectrum is acquired using one time record, Compensated Synchronous Detection (CSD). This parallel method enables battery diagnostics. The excitation current to a test battery is a sum of equal amplitude sin waves of a few frequencies spread over range of interest. The time profile of this signal has duration that is a few periods of the lowest frequency. The voltage response of the battery, average deleted, is the impedance of the battery in the time domain. Since the excitation frequencies are known, synchronous detection processes the time record and each component, both magnitude and phase, is obtained. For compensation, the components, except the one of interest, are reassembled in the time domain. The resulting signal is subtracted from the original signal and the component of interest is synchronously detected. This process is repeated for each component.Type: GrantFiled: July 5, 2007Date of Patent: July 1, 2008Assignee: Montana Tech of the University of MontanaInventors: John L. Morrison, William H. Morrison
-
Patent number: 7314906Abstract: A method of producing high molecular weight stereoregular head, tail-poly(alkylene D-glucaramides) is described. Amidoamino acids are esterified in cold alcohol and then polymerized in a protic solvent to form steroregular prepolymers. The prepolymers are then further polymerized by dissolving them in a solvent to form larger, purer postpolymers. Compositions of matter prepared using the subject method are also described.Type: GrantFiled: December 10, 2003Date of Patent: January 1, 2008Assignee: The University of MontanaInventors: Donald E. Kiely, Kylie Kramer
-
Patent number: 7314507Abstract: A metallic filter effectively removes mercury vapor from gas streams. The filter captures the mercury which then can be released and collected as product. The metallic filter is a copper mesh sponge plated with a six micrometer thickness of gold. The filter removes up to 90% of mercury vapor from a mercury contaminated gas stream.Type: GrantFiled: November 19, 2004Date of Patent: January 1, 2008Assignee: Montana Tech of The University of MontanaInventor: Kumar Ganesan